BMS-587101

• CAT Number: I004596
• CAS Number: 509083-77-6
• Molecular Formula: C26H20Cl2N4O4S
• Molecular Weight: 555.43
• Purity: ≥95%
• Synonyms: BMS-587101; BMS 587101; BMS587101; UNII-5V7E4UQL93.;5-[[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl]methyl]thiophene-3-carboxylic acid
• Target: Integrin
• Solubility: Soluble in DMSO, not in water
• Storage: Store at - 4 °C
• IUPAC Name: 5-[[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl]methyl]thiophene-3-carboxylic acid
• InChI: InChI=1S/C26H20Cl2N4O4S/c1-30-25(36)32(20-8-18(27)7-19(28)9-20)24(35)26(30)14-31(11-21-6-17(13-37-21)23(33)34)12-22(26)16-4-2-15(10-29)3-5-16/h2-9,13,22H,11-12,14H2,1H3,(H,33,34)/t22-,26+/m0/s1
• InChIKey: NXNKJLOEGWSJGI-BKMJKUGQSA-N
• SMILES: CN1C(=O)N(C(=O)C12CN(CC2C3=CC=C(C=C3)C#N)CC4=CC(=CS4)C(=O)O)C5=CC(=CC(=C5)Cl)Cl

BMS-587101 (CAT: I004596) is an LFA-1 (lymphocyte function-associated antigen-1) antagonist. LFA-1 is a cell surface protein found on various immune cells, including T cells and natural killer cells. By blocking the interaction of LFA-1 with its ligand intercellular adhesion molecule-1 (ICAM-1), BMS-587101 inhibits the adhesion and activation of immune cells, leading to a reduction in inflammation. In murine models of arthritis, BMS-587101 has demonstrated the ability to reduce joint inflammation and limit joint destruction, highlighting its potential as a therapeutic agent for inflammatory joint diseases.

Overview of Clinical Research

BMS-587101 is a lymphocyte function-associated antigen-1 inhibitor. The phase-II clinical trials in Inflammation in USA (PO) initiated in 2006. 

Reference

1:Metabolite generation via microbial biotransformations with Actinomycetes: rapid screening for active strains and biosynthesis of important human metabolites of two development-stage compounds, 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non7-yl-methyl]-3-thiophenecarboxylic acid (BMS-587101) and dasatinib. Li W, Josephs JL, Skiles GL, Humphreys WG.Drug Metab Dispos. 2008 Apr;36(4):721-30. doi: 10.1124/dmd.107.019570. Epub 2008 Jan 28. PMID: 18227141 Free Article
2:Discovery and development of 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl-methyl]-3-thiophenecarboxylic acid (BMS-587101)–a small molecule antagonist of leukocyte function associated antigen-1. Potin D, Launay M, Monatlik F, Malabre P, Fabreguettes M, Fouquet A, Maillet M, Nicolai E, Dorgeret L, Chevallier F, Besse D, Dufort M, Caussade F, Ahmad SZ, Stetsko DK, Skala S, Davis PM, Balimane P, Patel K, Yang Z, Marathe P, Postelneck J, Townsend RM, Goldfarb V, Sheriff S, Einspahr H, Kish K, Malley MF, DiMarco JD, Gougoutas JZ, Kadiyala P, Cheney DL, Tejwani RW, Murphy DK, Mcintyre KW, Yang X, Chao S, Leith L, Xiao Z, Mathur A, Chen BC, Wu DR, Traeger SC, McKinnon M, Barrish JC, Robl JA, Iwanowicz EJ, Suchard SJ, Dhar TG.J Med Chem. 2006 Nov 30;49(24):6946-9. PMID: 17125246